A drug used with misoprostol for medical abortion; central to abortion-pill access debates
The Supreme Court is weighing an emergency petition to pause a Fifth Circuit ruling that would restrict mifepristone access, while allowing telemedicine and mail delivery to continue for now. The government and manufacturers urge a rapid decision, as lower-court moves threaten broad abortion access.
The Supreme Court has issued an emergency order keeping mifepristone available by mail and via telehealth while litigation continues. The action preserves access as lawsuits challenge FDA rules on prescribing the abortion pill, with a ruling likely not until next year.
California Attorney General Rob Bonta is pressing a lawsuit against Heartbeat International and RealOptions Obria over abortion-pill reversal claims, arguing they mislead women after the 2023 suit. The case, ongoing in Alameda County, centers on whether high-dose progesterone can reverse mifepristone and whether groups adequately warn of risks; closing arguments are set for September with a ruling expected within 90 days.